M1774 Human Mass Balance Study (DDRIVER Solid Tumors 303)
Conditions: Solid Tumor Interventions: Drug: M1774 [14C]M1774 microtracer; Drug: M1774 Sponsors: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
Conditions: Renal Cell Carcinoma Interventions: Biological: V940; Biological: Pembrolizumab; Biological: Placebo Sponsors: Merck Sharp& Dohme LLC; ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)
Conditions: Bladder Cancer Interventions: Biological: Pembrolizumab; Biological: V940; Other: Placebo Sponsors: Merck Sharp& Dohme LLC; ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Pemetrexed; Drug: Carboplatin; Drug: Antihistamine; Drug: H2 Receptor Antagonist; Drug: Acetaminophen (or equivalent); Drug: Dexamethasone (or equivalent) Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
Conditions: Vaccine Hesitancy Interventions: Behavioral: Storytelling; Behavioral: Learn More (Active Comparator) Sponsors: University of Massachusetts, Worcester; Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Conditions: Malaria Interventions: Other: Plasmodium falciparum; Drug: MK-7602; Drug: Artemether/lumefantrine; Drug: Primaquine; Drug: Artesunate; Drug: Atovaquone/proguanil Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Conditions: Carcinoma, Squamous Cell; Skin Neoplasms Interventions: Biological: Pembrolizumab; Biological: V940; Procedure: Surgery Sponsors: Merck Sharp& Dohme LLC; Moderna TX Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
Conditions: Renal Impairment Interventions: Drug: MK-8527 Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
FOSTER CITY, Calif.,& RAHWAY, N.J.--(BUSINESS WIRE) March 06, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Conditions: Chronic Cough Sponsors: Imperial College London; Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
Conditions: Alzheimer ' s Disease Interventions: Drug: MK-1167; Drug: Donepezil; Drug: Placebo Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Conditions: Melanoma Stage III; Melanoma Stage IV Interventions: Drug: L19IL2; Drug: L19TNF; Drug: L19IL2/L19TNF; Drug: KEYTRUDA ® Sponsors: Philogen S.p.A.; Merck Sharp& Dohme LLC Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)
Conditions: Bipolar I Disorder Interventions: Drug: MK-8189; Drug: Placebo Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Conditions: Pneumococcal Vaccines; Immunosuppression Interventions: Drug: 15-valent pneumococcal conjugate vaccine; Drug: 23-valent pneumococcal polysaccharide vaccine Sponsors: VA Sierra Nevada Health Care System; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
Conditions: Cervix Cancer; Cervical Cancer Interventions: Drug: Pembrolizumab; Drug: Lenvatinib Sponsors: University of Texas Southwestern Medical Center; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
